Congratulations to NPS Pharmaceuticals

Congratulations to NPS Pharmaceuticals

NPS Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has approved Gattex® (Teduglutide [rDNA origin]) for Injection, for subcutaneous use for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. 

 Gattex will be available through our Specialty Pharmacy services in early 2013.